Addex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 […]
Clinical Insights & Research
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
The Syn-Sleep Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder
On Wednesday morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]
New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Treating Sleep Apnea Beyond the Clinic – Daybreak Case Study
Evaluating the efficacy of a virtual care model using mandibular advancement devices for mild to moderate obstructive sleep apnea By Steven Alvarado, Peter Balacky, DDS, Edward Kim, Daniel Moradzadeh, Julieanna Gonzalez, and Martin L. Hopp, MD, PhD A prevalent sleep disorder affecting an estimated 54 million people in the […]
New Survey Results Explore the Complexity of Marijuana Use and Sleep
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
For Older Adults with Mild Cognitive Impairment, Exercise Can Be Crucial to Sleep Quality
Staying active is known to improve sleep, but the research findings are mixed regarding the best workout. Some studies say light walking or stretching is best, others prefer moderate-intensity workouts like jogging — and some even find that vigorous exercise such as swimming makes sleep worse. Resolving this discrepancy is […]
Nexalin Study Shows Brain-Network Changes and Sleep Improvement in Chronic Insomnia
Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026. The study, titled: “Modulating […]
Alkermes Presents Phase 2 Alixorexton Data in Narcolepsy Type 1 at AAN 2026
Alkermes plc presents new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment […]













